Pharmacology of HIV integrase inhibitors

Current Opinion in HIV and AIDS

Volumn 7, Issue 5, 2012, Pages 390-400

  Adams, Jessica L ^a   Greener, Benjamin N ^a   Kashuba, Angela D M ^a,b  

^a University of North Carolina   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

dolutegravir; elvitegravir; HIV integrase inhibitors; raltegravir

Indexed keywords

ATAZANAVIR; BOCEPREVIR; COBICISTAT; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; DARUNAVIR; DOLUTEGRAVIR; ELVITEGRAVIR; EMTRICITABINE; ENFUVIRTIDE; GLUCURONOSYLTRANSFERASE 1A10; LERSIVIRINE; RALTEGRAVIR; RIBAVIRIN; RIFABUTIN; RIFAMPICIN; RILPIVIRINE; RITONAVIR; TENOFOVIR; TIPRANAVIR;

ADJUVANT THERAPY; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAXIMUM PLASMA CONCENTRATION; MIXED INFECTION; MONOTHERAPY; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; REVIEW; TABLET FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION;

HETEROCYCLIC COMPOUNDS, 3-RING; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; PYRROLIDINONES; QUINOLONES; UNITED STATES;

EID: 84865653643     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e328356e91c     Document Type: Review

References (65)

1. Markowitz M, Morales-Ramirez JO, Nguyen BY, et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naíve HIV-1-infected individuals. J Acquir Immune Defic Syndr 2006; 43:509-515.
2. Kassahun K, McIntosh I, Cui D, et al. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab Dispos 2007; 35:1657- 1663.
3. Isentress [package insert]. Whitehouse Station, NJ: Merck & Co. Inc.; 2011.
4. Ramanathan S, Mathias AA, German P, Kearney BP. Clinical pharmacokineticand pharmacodynamic profile of the HIV integrase inhibitor elvitegravir. ClinPharmacokinet 2011; 50:229-244.
5. DeJesus E, Berger D, Markowitz M, et al. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. J Acquir Immune Defic Syndr 2006; 43:1-5.
6. Mathias AA, West S, Hui J, et al. Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure. Clin Pharmacol Ther 2009; 85:64-70.
7. German P, Warren D, West S, et al. Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dosecombination regimen for the treatment of HIV. J Acquir Immune Defic Syndr 2010; 55:323-329.
8. German P, Warren D, Wei L, et al. Effect of food on pharmacokinetics of elvitegravir, emtricitabine, tenofovir DF and the pharmacoenhancer GS-9350 as a fixed-dose combination tablet. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 12-15, 2009; San Francisco, CA. Poster A1-1300.
9. German P, Wei X, Mizuno V, et al. Pharmacokinetics of elvitegravir and cobicistat in subjects with severe renal impairment. 13th International Workshop on Clinical Pharmacology of HIV Therapy; April 16-18, 2012; Barcelona, Spain. Abstract P/38.
10. Ramanathan S, Rhee M, Shen G, et al. Pharmacokinetics and safety of boosted-elvitegravir in subjects with hepatic impairment. 13th International Workshop on Clinical Pharmacology of HIV Therapy; April 16-18, 2012; Barcelona, Spain. Abstract P/40.
11. Min S, Song I, Borland J, et al. Pharmacokinetics and safety of S/ GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother 2010; 54:254-258.
12. Min S, Sloan L, DeJesus E, et al. Antiviral activity, safety, and pharmacokinetics/ pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1- infected adults. AIDS 2011; 25:1737-1745. This study provides a comprehensive evaluation of dolutegravir pharmacokinetics, inter-patient variability, and pharmacodynamics following multiple doses.
13. Song I, Borland J, Chen S, et al. Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravir. Antimicrob Agents Chemother 2012; 56:1627-1629. This study concluded that although food results in higher dolutegravir exposure, this change is unlikely to alter safety or efficacy.
14. Song I, Borland J, Savina P, et al. Pharmacokinetics of dolutegravir in subjects with moderate hepatic impairment. 19th Conference on Retroviruses and Opportunistic Infections; March 5-8, 2012; Seattle, WA. Paper #608.
15. Cattaneo D, Gervasoni C, Meraviglia P, et al. Inter- and intra-patient variability of raltegravir pharmacokinetics in HIV-1 infected subjects. J Antimicrob Chemother 2012; 67:460-464. HIV-infected patients on a regimen containing raltegravir had raltegravir concentrations measured over 4 h at two consecutive visits and showed highly variable pharmacokinetics both between patients and within the same patients on different days.
16. Eron JJ, Rockstroh JK, Reynes J, et al. Raltegravir once daily or twice daily in previously untreated patients with HIV-1: A randomized, active-controlled, phase 3 noninferiority trial. Lancet Infect Dis 2011; 11:907-915. Raltegravir 800mg once daily produced virologic response rates of 83% compared with 89% for raltegravir 400mg twice daily, but the time to achieve confirmed virologic response was longer in the once-daily group and there were lower response rates for patients with baseline viral loads above 100 000 copies/ml or with CD4 cell counts below 200 cells/ul. The authors concluded that raltegravir 800mg once daily cannot be recommended in place of 400 mg twice daily.
17. Nachman S, Samson P, Acosta E, et al. Pharmacokinetic (PK), safety, and efficacy data on cohort IIA: youth aged 6 to 11 years from IMPAACT P1066: A phase I/II study to evaluate raltegravir (RAL) in HIV-1 infected youth. 17th Conference on Retroviruses and Opportunistic Infections; Feb 16-19, 2010; San Francisco, CA. Paper #873.
18. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. October 14, 2011; 1-167. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescent GL.pdf. Accessed March 2012.
19. Brainard DM, Gendrano IN, Jin B, et al. A pharmacologic comparison of adult and pediatric formulations of raltegravir (RAL) in healthy adults. 17th Conference on Retroviruses and Opportunistic Infections; February 16-19, 2010; San Francisco, CA. Paper #872.
20. Wenning LA, Hanley WD, Brainard DM, et al. Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother 2009; 53:2852-2856.
21. Iwamoto M, Wenning LA, Petry AS, et al. Atazanavir modestly increases plasma levels of raltegravir in healthy subjects. Clin Infect Dis 2008; 47:137- 140.
22. Jackson A, Watson V, Back D, et al. Plasma and intracellular pharmacokinetics of darunavir/ritonavir once daily and raltegravir once and twice daily in HIV-1 infected individuals. J Acquir Immune Defic Syndr 2011; 58:450-457. The interaction between raltegravir and darunavir was assessed in HIV-positive patients on an ARV regimen. Overall, no remarkable interactions were seen between raltegravir and darunavir.
23. Goldwirt L, Braun J, de Castro N, et al. Switch from enfuvirtide to raltegravir lowers plasma concentrations of darunavir and tipranavir: A pharmacokinetic substudy of the EASIER-ANRS 138 trail. Antimicrob Agents Chemother 2011; 55:3613-3615. The concentrations of darunavir and tipranavir were measured in HIV-infected patients before and after switching from enfuvirtide to raltegravir. AUC, trough concentrations, and Cmax were decreased for both darunavir and tipranavir, but the clinical impact of those decreases is unknown.
24. Hanley WD, Wenning LA, Moreau A, et al. Effect of tipranavir-ritonavir on pharmacokinetics of raltegravir. Antimicrob Agents Chemother 2009; 53:2752-2755.
25. Vourvahis M, Langdon G, LaBadie RR, et al. Pharmacokinetic effects of coadministration of lersivirine with raltegravir or maraviroc in healthy subjects. Antimicrob Agents Chemother 2012; 56:887-892. The concentration changes of raltegravir when co-administered with lersivirinewere measured at steady state. Clinically nonsignificant decrease in mean AUCand Cmax were observed, and increase in mean trough concentrations.
26. Crauwels H, Stevens M, De La Rosa G, Boven K. Absence of pharmacokineticinteraction between the NNRTI rilpivirine (TMC278) and the integrase inhibitor raltegravir. 19th Conference on Retroviruses and OpportunisticInfections; Mar 5-8 2012; Seattle, WA. Paper #617.
27. HIV and Viral Hepatitis. Center for Disease Control and Prevention. Atlanta,GA. Available from: http://www.cdc.gov/hiv/resources/factsheets/ hepatitis.htm. Last Updated 17 Nov 2011. Accessed March 2012.
28. Ashby J, Garvey L, Erlwein OW, et al. Pharmacokinetic and safety profile ofraltegravir and ribavirin, when dosed separately and together, in healthyvolunteers. J Antimicrob Chemother 2011; 66:1340-1345.The interaction between raltegravir and ribavirin was assessed in healthyvolunteers. No significant differences in the pharmacokinetic parameters of raltegravirwere observed, but the ribavirin Cmax was decreased and Tmax increased.
29. de Kanter C, Blonk M, Colbers A, et al. The influence of the HCV protease inhibitor bocepravir on the pharmacokinetics of the HIV integrase inhibitor raltegravir. 19th Conference on Retroviruses and Opportunistic Infections;Mar 5-8, 2012; Seattle, WA. Paper #772LB. The interaction between bocepravir and raltegravir was assessed in healthy individuals and bocepravir was not found to affect raltegravir exposure.
30. van Heeswijk R, Garg V, Boogaerts G, et al. The pharmacokinetic interaction between telaprevir and raltegravir in healthy volunteers. 51st InterscienceConference on Antimicrobial Agents and Chemotherapy; Se 17-20, 2012; Chicago, IL. LB A1-1738a. The interaction between telaprevir and raltegravir was studied in healthvolunteers and a clinically insignificant increase in raltegravir exposures wasobserved.
31. Reinbach B, de Sousa G, Dostert P, et al. Comparative effects of rifabutin and rifampicin on cytochromes P450 and UDP-glucuronosyl-transferases expression in fresh and cryopreserved human hepatocytes. Chem BiolInteract 1999; 121:37-48.
32. Brainard DM, Kassahun K, Wenning LA, et al. Lack of a clinically meaningful pharmacokinetic effect of rifabutin on raltegravir: in vitro/in vivo correlation.J Clin Pharmacol 2011; 51:943-950. Rifabutin was not found to alter raltegravir pharmacokinetics to a clinically meaningful extent in vivo.
33. Wenning LA, Friedman EJ, Kost JT, et al. Lack of a significant drug interaction between raltegravir and tenofovir. Antimicrob Agents Chemother 2008;52:3253-3258.
34. Kiser JJ, Bumpass JB, Meditz AL, et al. Effect of antacids on the pharmacokinetics of raltegravir in human immunodeficiency virus-seronegative volunteers. Antimicrob Agents Chemother 2010; 54:4999-5003.
35. Ramanathan R, Shen G, Hinkle J, et al. Pharmacokinetics of coadministered ritonavir-boosted elvitegravir and zidovudine, didanosine, stavudine, orabacavir. J Acquir Immune Defic Syndr 2007; 46:160-166.
36. Ramanathan S, Shen G, Cheng A, et al. Pharmacokinetics of emtricitabine, tenofovir, and GS-9137 following coadministration of emtricitabine/tenofovir disoproxil fumarate and ritonavir-boosted GS-9137. J Acquir Immune DeficSyndr 2007; 45:274-279.
37. Ramanathan S, Kakuda TN, Mack R, et al. Pharmacokinetics of elvitegravir and etravirine following coadministration of ritonavir-boosted elvitegravir and etravirine. Antivir Ther 2008; 13:1011-1017.
38. Mathias AA, Hinkle J, Shen G, et al. Effect of ritonavir-boosted tipranavir or darunavir on the steady-state pharmacokinetics of elvitegravir. J Acquir Immune Defic Syndr 2008; 49:156-162.
39. Ramanathan S, Mathias AA, Shen G, et al. Lack of clinically relevant drug-drug interaction between ritonavir-boosted GS-9137 (elvitegravir) and fosamprenavir/r. 4th IAS Conference on HIV Pathogenesis, Treatment, and Prevention; July 22-25, 2007; Sydney, Australia. Abstract WEPEB014.
40. Mathias A, Ramanathan S, Hinkle J, et al. Effect of atazanavir/r on the steady state pharmacokinetics of elvitegravir. 47th Interscience Conferenceon Antimicrobial Agents and Chemotherapy; September 17-20, 2007;Chicago, IL. Abstract A-1417.
41. Ramanathan S, Wang H, Stondell T, et al. Pharmacokinetics and drug interaction profile of cobicistat boosted-EVG with atazanavir, rosuvastatinor rifabutin. 13th International Workshop on Clinical Pharmacology of HIV Therapy; Apr 16-18, 2012; Barcelona, Spain. Abstract O/03. Co-administration of rifabutin and cobicistat-boosted elvitegravir resulted intrough concentrations lower than those expected from data with rifabutin and ritonavir-boosted elvitegravir. This study also assessed pharmacokinetics forelvitegravir/cobicistat administered with atazanavir or rosuvastatin.
42. Mathias A, Ramanathan S, Hinkle J, et al. A pharmacokinetic interaction between lopinavir/r and elvitegravir. 47th Interscience Conference on AntimicrobialAgents and Chemotherapy; September 17-20, 2007; Chicago, IL.Abstract A-1418.
43. Ramanathan S, Abel S, Tweedy S, et al. Pharmacokinetic interaction ofritonavir-boosted elvitegravir and maraviroc. J Acquir Immune Defic Syndr2010; 53:209-214.
44. German P, West S, Hui J, et al. Pharmacokinetic interaction between elvitegravir/ritonavir and dose-adjusted rifabutin. 9th International Workshopon Clinical Pharmacology of HIV Therapy; April 7-9, 2008; New Orleans, LA. Abstract P19.
45. Ramanathan S, Shen G, Hinkle J. Pharmacokinetic evaluation of drug interactions with ritonavir-boosted HIV integrase inhibitor GS-9137 (elvitegravir)-and acid-reducing agents. 8th International Workshop on ClinicalPharmacology of HIV Therapy; April 16-18, 2007; Budapest, Hungary. Abstract 69.
46. Mathias A, Koziara J, Wei L, et al. Effect of acid reducing agents on the relativebioavailability and pharmacokinetics of cobicistat-boosted elvitegravir. 12thInternational Workshop on Clinical Pharmacology of HIV Therapy; April 13- 15, 2011; Miami, FL. Abstract P/13.
47. Song I, Min SS, Borland J, et al. Lack of interaction between the HIV integrase inhibitor S/GSK1349572 and tenofovir in healthy subjects. J Acquir ImmuneDefic Syndr 2010; 55:365-367.
48. Song I, Borland J, Lou Y, et al. Effects of enzyme inducers, tipranavir and efavirenz, on the pharmacokinetics of the integrase inhibitor, dolutegravir (S/GSK1359572). 12th International Workshop onClinical Pharmacology of HIV Therapy; April 13-15, 2011; Miami, FL.Abstract O/02.Although significant decreases in dolutegravir exposure are observed withboth tipranavir and efavirenz, dolutegravir trough concentrations remain multi-foldabove the IC90.
49. Song I, Borland J, Min S, et al. Effects of etravirine alone and with ritonavir-boosted protease inhibitors on the pharmacokinetics of dolutegravir.Antimicrob Agents Chemother 2011; 55:3517-3521. This article explains the clinically important interaction between etravirineand dolutegravir and rescue of dolutegravir's pharmacokinetic profile by coadministrationof boosted protease inhibitors.
50. Song I, Min SS, Borland J, et al. The effect of lopinavir/ritonavir and darunavir/ ritonavir on the HIV integrase inhibitor S/GSK1349572 in healthy participants. J Clin Pharmacol 2011; 51:237-242.This study provides evidence that dolutegravir does not participate in clinicallyimportant interactions with the protease inhibitors lopinavir/ritonavir and darunavir/ritonavir.
51. Song I, Borland J, Chen S, et al. Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor,S/GSK1349572. Br J Clin Pharmacol 2011; 72:103-108. Although the investigators observed significant increases in dolutegravir exposurewith atazanavir and atazanavir/ritonavir, likely due to UGT inhibition, they concludethat these changes are unlikely to negatively impact therapy.
52. Song I, Borland J, Chen S, et al. Effect of fosamprenavir/ritonavir on the pharmacokinetics of the integrase inhibitor, dolutegravir, in healthy subjects. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy;September 17-20, 2011; Chicago, IL. Abstract A1-1727.
53. Dooley KE, Purdy E, Sayre P, et al. Safety, tolerability, and pharmacokinetics ofthe HIV integrase inhibitor dolutegravir given twice daily with rifampin: resultsof a Phase I study among healthy subjects. 19th Conference on Retrovirusesand Opportunistic Infections; March 5-8, 2012; Seattle, WA. Paper #148.This abstract provides evidence for increased dolutegravir dosing frequency whenadministered with rifampin.
54. Dooley KE, Sayre P, Borland J, et al. Pharmacokinetics, safety, and tolerability of the HIV integrase inhibitor dolutegravir co-administered with rifabutin inhealthy subjects. 13th International Workshop on Clinical Pharmacology ofHIV Therapy; April 16-18, 2012; Barcelona, Spain. Abstract P/11.Rifabutin can be co-administered with dolutegravir without dose adjustment,despite a 30% decrease in dolutegravir trough concentration.
55. Patel P, Song I, Borland J, et al. Pharmacokinetics of the HIV integraseinhibitor S/GSK1349572 co-administered with acid-reducing agents and multivitamins in healthy volunteers. J Antimicrob Chemother 2011; 66:1567-1572.This article highlights the clinically important interaction between antacids anddolutegravir.
56. Ramanathan S, Mathias AA, Hinkle J, Kearney BP. Clinical pharmacology of the HIV integrase inhibitor elvitegravir. 11th European AIDS Conference; October 24-27, 2007; Madrid, Spain. Abstract PS4/7.
57. DeJesus E, Rockstroh J, Henry K, et al. Week 48 results of an ongoing phase 3 study comparing elvitegravir/cobicistat/emtricitabine/tenofovir (Quad) with atazanavir/ritonavir plus emtricitabine/tenofovir in treatment-naíve HIV-1; subjects showing efficacy, safety, and pharmacokinetics. 19th Conference on Retroviruses and Opportunistic Infections; March 5-8, 2012; Seattle, WA. Paper #627.
58. Sax P, DeJesus E, Millis A, et al. Elvitegravir/cobicistat/emtricitabine/ tenofovir (Quad) has noninferior efficacy and favorable safety compared to efavirenz/ emtricitabine/tenofovir in treatment-naíve HIV-1; subjects. 19th Conference on Retroviruses and Opportunistic Infections; March 5-8, 2012; Seattle, WA. Paper #101.
59. Molina JM, Lamarca A, Andrade-Villanueva J, et al. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, doubleblind, phase 3, noninferiority study. Lancet Infect Dis 2012; 12:27-35. This phase 3 clinical trial evaluates the safety and efficacy of once-daily ritonavirboosted elvitegravir with raltegravir as an active comparator.
60. Soriano V, Cox J, Eron JJ, et al. Dolutegravir (DTG, s/GSK1349572) treatment of subjects with raltegravir (RAL) resistance: viral suppression at week 24 inVIKING study. 13th European AIDS Conference; October 12-15, 2011; Belgrade, Serbia. Abstract PS1/2.
61. van Lunzen J, Maggiolo F, Arribas JR, et al. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis 2012; 12:111-118. This phase 3 clinical trial provides evidence for the efficacy and safety of dolutegravir in treatment-naíve patients.
62. Eron JJ, Kumar P, Lazzarin A, et al. DTG in subjects with HIV exhibiting RAL resistance: Functional monotherapy results of VIKING study cohort II. 18th Conference on Retroviruses and Opportunistic Infections; Feb 27-Mar 2, 2011; Boston, MA. Paper #151LB
63. Stellbrink HJ, Reynes J, Lazzarin A, et al. Dolutegravir in combination therapy exhibits rapid and sustained antiviral response in ARV-naive adults: 96-week results from SPRING-1 (ING112276). 19th Conference on Retroviruses and Opportunistic Infections; March 5-8, 2012; Seattle, WA. Paper #102LB.
64. Patel P, Song I, Borland J, et al. Pharmacokinetics of a dolutegravir pediatric granule formulation in healthy adult subjects. 19th Conference on Retroviruses and Opportunistic Infections; March 5-8, 2012; Seattle, WA. Paper #985.
65. Protocol Summaries: GSK1265744 [Internet]. 2012 [cited 2012 May 31]. Available from: http://www.gskclinicalstudyregister.com/protocol/comp/list. jsp;jsessionid02043C0461BBAF033065BDD0C951F31C? compoundGsk1265744.